Thermo Fisher Scientific Inc.

NYSE TMO

Thermo Fisher Scientific Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 34.72

Thermo Fisher Scientific Inc. Price to Earnings Ratio (P/E) is 34.72 on January 14, 2025, a 0.40% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Thermo Fisher Scientific Inc. 52-week high Price to Earnings Ratio (P/E) is 38.56 on September 30, 2024, which is 11.06% above the current Price to Earnings Ratio (P/E).
  • Thermo Fisher Scientific Inc. 52-week low Price to Earnings Ratio (P/E) is 31.25 on November 18, 2024, which is -10.00% below the current Price to Earnings Ratio (P/E).
  • Thermo Fisher Scientific Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 35.68.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: TMO

Thermo Fisher Scientific Inc.

CEO Mr. Marc N. Casper
IPO Date March 17, 1980
Location United States
Headquarters 168 Third Avenue
Employees 122,000
Sector Health Care
Industries
Description

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Similar companies

IDXX

IDEXX Laboratories, Inc.

USD 418.63

-0.94%

ILMN

Illumina, Inc.

USD 136.48

-5.37%

RVTY

Revvity, Inc.

USD 120.73

-1.61%

GH

Guardant Health, Inc.

USD 37.46

-1.68%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

WAT

Waters Corporation

USD 404.93

1.26%

A

Agilent Technologies, Inc.

USD 143.43

1.04%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

DHR

Danaher Corporation

USD 237.62

-0.94%

StockViz Staff

January 15, 2025

Any question? Send us an email